Results 71 to 80 of about 8,788 (204)

Post‐COVID‐19 Area Postrema Syndrome With SARS‐CoV‐2 in CSF: A Dual‐Case Report and Review of the Literature

Immunity, Inflammation and Disease, Volume 14, Issue 4, April 2026.
This dual‐case report describes two patients with post‐COVID‐19 area postrema syndrome whose outcomes were dictated by their AQP4‐IgG serostatus, despite both having SARS‐CoV‐2 detected in their CSF. The stark contrast between the seronegative patient's recovery and the seropositive patient's fatal relapse highlights antibody testing as an urgent and ...
Wan Zhu, Jing Qian, Min Peng, Yan Li, Jinghan Hu   +4 more
wiley   +1 more source

Mitigating Paxlovid™-induced drug‒drug interaction toxicity: an in silico insight

Frontiers in Pharmacology
The clinical drug-drug interaction side-effects of Ritonavir, an ingredient in Paxlovid™, have been documented, highlighting the need to explore alternative administration methods for Nirmatrelvir, another drug in the Paxlovid™ combination. In this study,
Giang H. Ta, Max K. Leong
doaj   +1 more source

Development and validation of a new stability indicating RP-UPLC method for the simultaneous estimation of Nirmatrelvir and Ritonavir in presence of internal standard (Velpatasvir) [PDF]

A new stability indicating RP-UPLC method has been proposed for the simultaneous estimation of Nirmatrelvir and Ritonavir in presence of an internal standard, Velpatasvir using Waters ACQUITY UPLC system with PDA detector and Hibar C18 (100 x 2.1 mm, 1.8)
Asia, Revu Baby Nalanda
core   +1 more source

The oral nucleoside prodrug GS-5245 is efficacious against SARS-CoV-2 and other endemic, epidemic, and enzootic coronaviruses [PDF]

Despite the wide availability of several safe and effective vaccines that prevent severe COVID-19, the persistent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) that can evade vaccine-elicited ...
Adams, Lily E, Babusis, Darius, Bannister, Roy, Baric, Ralph S, Baric, Thomas J, Barrett, Kimberly T, Bilello, John P, Brown, Ariane J, Catanzaro, Nicholas J, Cihlar, Tomas, Conrad, Helen, De la Cruz, Gabriela, Diefenbacher, Meghan V, Dong, Stephanie, Feng, Joy Y, Gully, Kendra L, Kalla, Rao, Mackman, Richard L, Mallory, Michael L, Martinez, David R, May, Samantha R, Montgomery, Stephanie A, Moreira, Fernando R, Nguyen, Anh-Hoa, Nguyen, Anh-Quan, Nguyen, Cameron, Perry, Jason K, Schäfer, Alexandra, Scobey, D Trevor, Sheahan, Timothy P, Yount, Boyd, Zweigart, Mark R   +31 more
core   +2 more sources

Antivirals Targeting Coronavirus RNA‐Dependent RNA Polymerase and Main Protease: From Mechanisms of Action to Outcomes in COVID‐19 Clinical Trials

Microbial Biotechnology, Volume 19, Issue 4, April 2026.
The target sites of COVID‐19 antivirals discussed in the present opinion paper, namely the RNA dependent RNA polymerase Nsp12 and of the main viral protease Nsp5, are indicated by a red star in the overview of the replication cycle of coronavirus SARS‐CoV‐2.
Harald Brüssow
wiley   +1 more source

Effectiveness of Vaccines and Antiviral Drugs in Preventing Severe and Fatal COVID-19, Hong Kong

Emerging Infectious Diseases
We compared the effectiveness and interactions of molnupiravir and nirmatrelvir/ritonavir and 2 vaccines, CoronaVac and Comirnaty, in a large population of inpatients with COVID-19 in Hong Kong. Both the oral antiviral drugs and vaccines were associated
Yue Yat Harrison Cheung, Eric Ho Yin Lau, Guosheng Yin, Yun Lin, Benjamin J. Cowling, Kwok Fai Lam   +5 more
doaj   +1 more source

Pharmacokinetics and Safety of Single and Multiple Doses of Molnupiravir in Healthy Male Chinese Adults: An Open‐Label, Fixed Sequence, Phase 1 Study

Clinical and Translational Science, Volume 19, Issue 4, April 2026.
ABSTRACT Molnupiravir is an orally administered prodrug of β‐D‐N4‐hydroxycytidine (NHC) that is conditionally approved in China for the treatment of mild to moderate COVID‐19 in nonhospitalized adults at high risk of disease progression. Molnupiravir is rapidly absorbed and hydrolyzed to deliver NHC into systemic circulation.
Jixiang Zhu, Danning Zhang, Zhiping Liu, Bei Yan, Yanqiao Zang, Weiwei Zhao, Fang Sun, Brian M. Maas, Mickie H. Cheng, S. Aubrey Stoch, Haiyan Li   +10 more
wiley   +1 more source

Fixing the Achilles Heel of Pfizer’s Paxlovid for COVID-19 Treatment [PDF]

Nirmatrelvir (PF-07321332), a first-in-class inhibitor of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) main protease (Mpro), was developed by Pfizer under intense pressure during the pandemic to treat COVID-19.
Brewitz, Lennart, Schofield, Christopher J.   +1 more
core   +2 more sources

Cost-effectiveness of nirmatrelvir/ritonavir in COVID-19 patient groups at high risk for progression to severe COVID-19 in the Netherlands [PDF]

Background: Nirmatrelvir/ritonavir is indicated for the treatment of COVID-19 in symptomatic adults with increased risk for severe illness, not requiring supplemental oxygen yet.
Arteaga Duarte, Carlos H., de Goeij, Michelle H.M., Peters, Michel L., Postma, Maarten J., Spijkerman, Roy   +4 more
core   +1 more source

Exploring Paxlovid Efficacy in COVID-19 Patients with MAFLD: Insights from a Single-Center Prospective Cohort Study

Viruses
This study investigates the intricate interplay between Metabolic-associated Fatty Liver Disease (MAFLD) and COVID-19, exploring the impact of MAFLD on disease severity, outcomes, and the efficacy of the antiviral agent Paxlovid (nirmatrelvir/ritonavir).
Mykhailo Buchynskyi, Valentyn Oksenych, Iryna Kamyshna, Oleksandr Kamyshnyi   +3 more
doaj   +1 more source